The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL

American Journal of Hematology, Journal Year: 2023, Volume and Issue: 98(12), P. 1856 - 1868

Published: Sept. 29, 2023

Abstract In this retrospective international multicenter study, we describe the clinical characteristics and outcomes of patients with chronic lymphocytic leukemia (CLL) related disorders (small lymphoma high‐count monoclonal B lymphocytosis) infected by SARS‐CoV‐2, including development post‐COVID condition. Data from 1540 CLL SARS‐CoV‐2 January 2020 to May 2022 were included in analysis assigned four phases based on cases disposition variants emergence. Post‐COVID condition was defined according WHO criteria. Patients during most recent pandemic, though carrying a higher comorbidity burden, less often hospitalized, rarely needed intensive care unit admission, or died compared initial phases. The 4‐month overall survival (OS) improved through phases, 68% 83%, p = .0015. Age, comorbidity, CLL‐directed treatment, but not vaccination status, emerged as risk factors for mortality. Among survivors, 6.65% had reinfection, usually milder than one, 16.5% developed latter characterized fatigue, dyspnea, lasting cough, impaired concentration. Infection severity only factor developing post‐COVID. median time resolution 4.7 months. OS different likely due improvement prophylactic therapeutic measures against well emergence variants. However, mortality remained relevant significant number conditions, warranting further investigations.

Language: Английский

---

Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: June 22, 2023

The approved combination of Tixagevimab/Cilgavimab has been shown to decrease the rate symptomatic SARS-CoV-2 infection in patients at increased risk inadequate response vaccination. However, was tested a few studies that included with hematological malignancies, even if this population an unfavorable outcomes following (with high rates hospitalization, intensive care unit admission, and mortality) poor significant immunization vaccines. We performed real-life prospective cohort study evaluate pre-exposure prophylaxis anti-spike seronegative compared seropositive who were observed or received fourth vaccine dose. recruited 103 mean age 67 years: 35 (34%) followed from March 17, 2022, until November 15, 2022. After median follow-up 4.24 months, 3-month cumulative incidence 20% versus 12% observation/vaccine groups respectively (HR 1.57; 95% CI: 0.65-3.56; p = 0.34). In study, we report our experience tailored approach prevention malignancies during omicron surge.

Language: Английский

---

Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

Annals of Hematology, Journal Year: 2024, Volume and Issue: 103(6), P. 2123 - 2131

Published: March 2, 2024

Language: Английский

---

Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan

International Journal of Hematology, Journal Year: 2023, Volume and Issue: 118(6), P. 731 - 736

Published: Sept. 25, 2023

Language: Английский

---